APOA5 anticorps (N-Term)

N° du produit ABIN965570

L’anticorps Lapin Polyclonal anti-APOA5 a été validé pour IHC. Il convient pour détecter APOA5 dans des échantillons de Humain, Rat et Souris.

Aperçu rapide pour APOA5 anticorps (N-Term) (ABIN965570)

Antigène: APOA5 (Apolipoprotein A-V (APOA5))

Reactivité: Humain, Rat, Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp APOA5 est non-conjugé

Application: Immunohistochemistry (IHC)

Détail du produit anti-APOA5 anticorps

Épitope: N-Term

Purification: Purified by antigen-specific affinity chromatography.

Immunogène: Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to N-terminal residues of human APOA5 (Apolipoprotein A-V precursor)

Information d'application

Indications d'application: ELISA, Western blotting: 1µg/ml for 2hrs.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: This antibody is stored in PBS, 50% glycerol

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Détails sur APOA5

Antigène: APOA5 (Apolipoprotein A-V (APOA5))

Autre désignation: APOA5

Sujet: APOA5(Apolipoprotein A-V) is a minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. APOA5 may also be associated with chylomicrons. APOA5 is an important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDLTG production rate (without affecting the VLDL-apoB production rate). Three common alleles are known: allele APOA5*1, APOA5*2 and APOA5*3. The APOA5*2 haplotype, which consists of 3 non-coding SNPs, is present in approximately 16% of Caucasians and is associated with increased plasma triglyceride concentrations. APOA5*3 haplotype is defined by the rare Ser-19-Trp substitution. Together, the APOA5*2 and APOA5*3 haplotypes are found in 25 to 50% of African Americans, Hispanics, and Caucasians.

Pathways: Regulation of Lipid Metabolism by PPARalpha, Lipid Metabolism